Skip to content
Biodatica
Start free

Akeso

Guanzhou, Guangdong

OncologybispecificPhase IIListed · 9926.HK

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

4mo agoTrial registeredMar 2, 2026Source filing (opens the source filing in a new tab)

Momentum

68no change

Momentum 68 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $633k · non-dilutive

    Apr 1, 2025

    UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, LIANGHUI · NHLBI · award ends Jan 31, 2029 · Pathogenic Mechanism and Therapeutic Approaches for Exercise Intolerance in Post-Acute Sequelae of COVID-19

    NIH RePORTER · NIH RePORTER 11019369 (opens the source filing in a new tab)

  2. Grant

    R01 · $686k · non-dilutive

    Apr 1, 2022

    BAYLOR COLLEGE OF MEDICINE · PI ZHANG, LILEI · NHLBI · award ends Mar 31, 2027 · Deciphering the role of a circadian lncRNA in cardiac remodeling

    NIH RePORTER · NIH RePORTER 11055423 (opens the source filing in a new tab)

  3. Grant

    R01 · $292k · non-dilutive

    Sep 30, 2021

    UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZHANG, LIYUN · NEI · award ends Jun 30, 2026 · Drug Screening for Neuroprotectants in Novel Zebrafish Models of Retinitis Pigmentosa

    NIH RePORTER · NIH RePORTER 11314801 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Feb 1, 2021

    NSCLC · ACTIVE_NOT_RECRUITING · sponsor: Akeso · A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

    ClinicalTrials.gov · NCT04736823 (opens the source filing in a new tab)

  5. Trial

    Study registered

    Jan 1, 2020

    Intertrochanteric Fractures, Internal Fixation Failure, CONUT Score, Nomogram Model, Nutritional Status · COMPLETED · sponsor: First Affiliated Hospital of Fujian Medical University · Controlling Nutritional Status as a Superior Predictor of Fixation Failure in Intertrochanteric Fractures: Development and Validation of a Multicentre Nomogram

    ClinicalTrials.gov · NCT07159945 (opens the source filing in a new tab)

  6. Grant

    P01 · $293k · non-dilutive

    Sep 1, 1997

    YALE UNIVERSITY · PI ZHANG, LE · NIAID · award ends Apr 30, 2028 · Core C: Subtractive Single Nucleus Seq and Spatial Multi-omics Core

    NIH RePORTER · NIH RePORTER 11084490 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources